Empowered Patient Podcast

Dr. Simrit Parmar, Founder of Cellenkos, is developing T regulatory cell therapies from cord blood to treat aplastic anemia, myelofibrosis, and acute lymphoblastic leukemia. Their three-prong strategy focuses on resolving inflammation and alleviating the burden of transfusions. Treg cells from cord blood are naturally tolerant and do not risk rejection, meaning they can be administered to patients without the need for matching. The cells can be consistently manufactured in a scalable way and distributed globally. Simrit explains, "Tregs, the T regulatory cells, are actually regulators of our immune system. So if you think about it every day as a human being, we face many challenges. We face many insults and injuries to our body, both externally and internally, but our body has a way to maintain that balance. The T regulatory cells are the cells that are the mastermind of making sure that any response by our body, for example, to get rid of an antigen or to get rid of an irritant does not overstay the welcome